News | Vitalis

VTS-72 aims to be the next generation oral fumarate therapy, that may hold potential as a treatment for MS with fewer side effects and other clinical benefits for these patients.

Aiming to submit NDA in 2020-2021.

VTS-72 aims to be the next generation oral fumarate therapy, that may hold potential as a treatment for MS with fewer side effects and other clinical benefits for these patients.

Aiming to submit NDA in 2020-2021.

VTS-K: Ketamine + VTS Aspirin for Postoperative Pain

VTS-K: Ketamine + VTS Aspirin for Postoperative Pain

Vitalis

Media

Potential RRMS Fumarate Treatment Free of ‘Flush’ Effect to Enter Trial in 2020, Vitalis Says

MS News Today

October 24, 2019

A new company enters the Tecfidera fight, offering to kill two birds

ENDPOINTSNEWS

October 22, 2019

BioWorld Today - October 23, 2019: Other news to note

BioWorld

subscription required to view full article

October 23, 2019

Vitalis Announces Plans for Low-Flush Formulation Fumarate VTS-72 In Multiple Sclerosis

NeurologyLive

October 24, 2019

Novel Aspirin Formulation May Address Bothersome MS Symptoms, Treatment Side Effects

NeurologyLive

January 10, 2020

Vitalis Plans to Launch Phase 3 Trial Testing VTS-72 as Treatment for RRMS-related Flushing

MS News Today

January 10, 2020

VTS-Aspirin Combos to Ease Flush in RRMS Named Orphan Drug by FDA

MS News Today

April 23, 2020

VTS-Aspirin Wins Orphan Status in Combination With Fumarates for Flush in MS

NeurologyLive

April 28, 2020